Liletta IUD Increase The Risk Of Breast Cancer. Our firm is investigating potential lawsuits on behalf of individuals who developed breast cancer after using Liletta intrauterine device (IUD), which was approved by the U.S. Food and Drug Administration (FDA) in March 2015. IUDs are contraceptive devices that are inserted into the uterus; some are hormonal while others are made of copper. Liletta, Sklya, and Mirena are all examples of hormonal IUDs that release levonorgestrel. Recent research suggests that these types of IUDs may increase the risk for developing breast cancer.
If you or someone you know developed breast cancer after using Liletta, please contact Parker Waichman LLP today.
Liletta, other Hormonal IUDs Linked to Higher Risk of Lobular and Ductal Breast Cancer
Researchers studied the link between levonorgestrel-releasing intrauterine systems (LNG-IUS) and breast cancer with the knowledge that there is an increased risk of breast cancer in post-menopausal women using LNG-IUS. The risks in premenopausal women, however, are debated. The findings, which were published in Acta Oncologica in June 2015, found that devices such Liletta, Sklya, and Mirena were linked to a higher risk of breast cancer.
The authors sought to test whether devices such as Liletta increased the risk of lobular breast cancer. They found that LNG-IUS use “is not only related to an excess risk of lobular cancer but also, contrary to previous assumptions, to an excess risk of ductal breast cancer.” Ductal breast cancer accounts for roughly 80 percent of all breast cancers, while lobular cancers account for 15 percent.
Researchers used data from the national Medical Reimbursement Registry of Finland to identify women between the ages of 30 and 49 who used levonorgestrel-releasing IUDs to treat or prevent menorrhagia (abnormally heavy menstrual bleeding) between 1994 and 2007. LNG-IUS devices are frequently used for menorrhagia. Data from the Finnish Cancer Registry was used to identify women diagnosed with breast cancer before the age of 55 and by the end of 2012.
A total of 2,015 were diagnosed with breast cancer in a cohort of 93,843 women using devices such as Liletta. Compared to the general population, use of LNG-IUS was associated with a higher risk of both lobular cancer and ductal breast cancer. Women who purchased the contraceptive at least twice had the highest risk. Compared to the general female population of similar age, they experienced a 73 percent greater likelihood of being diagnosed with lobular breast cancer.